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Worldwide,  colorectal  cancer  accounted  for  about  one  million 
newly diagnosed cancers in 2002, representing approximately 10% 
of  all  new  cancers  (1).  Estimated  5-year  survival  for  colorectal 
cancer is approximately 54% in Western Europe (1). Tumors in 
patients with inherited cancer syndromes may arise through dis-
tinct molecular genetic pathways and show histological features 
that are different from those in most sporadic tumors. These dif-
ferences  might,  at  least  in  part,  influence  tumor  behavior  and 
patient survival. For instance, mismatch repair–deficient tumors 
(associated with Lynch syndrome or sporadic microsatellite insta-
bility) have been reported to have a decreased likelihood of metas-
tasizing, and patients with such tumors have better survival than 
patients  with  sporadic  colorectal  cancer  (2–8),  although  some 
reports have not confirmed this finding (9–12).
In 2002, the first autosomal recessive inherited form of colo-
rectal  cancer,  MUTYH-associated  polyposis  (Mendelian 
Inheritance  in  Man  #608456),  was  described  (13).  MUTYH-
associated polyposis is believed to be responsible for 0.3%–1% of 
all colorectal cancers (14,15).
The MUTYH protein is a base excision repair glycosylase that 
is involved in the repair of DNA damage resulting from the oxida-
tion of guanine nucleotides. The oxidation product of guanine, 
8-oxo-7,8-dihydro-2′-deoxyguanosine  can  mispair  with  adenine, 
leading to a transversion in which a G:C base pair is replaced with 
a T:A base pair. The MUTYH protein prevents these transver-
sions  by  scanning  the  newly  synthesized  DNA  strand  for  any 
mispaired  adenines,  with  guanines  or  8-oxo-7,8-dihydro-2′-
deoxyguanosines, and excising them.
The  risk  of  colorectal  cancer  in  individuals  with  biallelic 
MUTYH mutations is high. The penetrance of colorectal cancer in 
patients with MUTYH-associated polyposis at age 60 years was 
estimated to be 100% in one study (16) and 43% in another (14).
We  hypothesized  that  survival  of  patients  with  MUTYH-
associated polyposis and colorectal cancer might differ from that of 
colorectal cancer patients from the general population because of 
the distinct mutational mechanism underlying MUTYH-associated 
polyposis.  The  purpose  of  this  study  was  to  compare  survival 
between  patients  with  MUTYH-associated  polyposis  colorectal 
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  Background  MUTYH-associated polyposis is a recessively inherited disorder characterized by a lifetime risk of colorectal 
cancer that is up to 100%. Because specific histological and molecular genetic features of MUTYH-associated 
polyposis  colorectal  cancers  might  influence  tumor  behavior  and  patient  survival,  we  compared  survival 
between patients with MUTYH-associated polyposis colorectal cancer and matched control patients with colo-
rectal cancer from the general population.
  Methods  In this retrospective multicenter cohort study from Europe, 147 patients with MUTYH-associated polyposis co-
lorectal cancer were compared with 272 population-based control patients with colorectal cancer who were 
matched for country, age at diagnosis, year of diagnosis, stage, and subsite of colorectal cancer. Kaplan–Meier 
survival and Cox regression analyses were used to compare survival between patients with MUTYH-associated 
polyposis colorectal cancer and control patients with colorectal cancer. All statistical tests were two-sided.
  Results  Five-year survival for patients with MUTYH-associated polyposis colorectal cancer was 78% (95% confidence 
interval [CI] = 70% to 84%) and for control patients was 63% (95% CI = 56% to 69%) (log-rank test, P = .002). After 
adjustment for differences in age, stage, sex, subsite, country, and year of diagnosis, survival remained better 
for MUTYH-associated polyposis colorectal cancer patients than for control patients (hazard ratio of death = 
0.48, 95% CI = 0.32 to 0.72).
  Conclusions  In  a  European  study  cohort,  we  found  statistically  significantly  better  survival  for  patients  with  MUTYH-
associated polyposis colorectal cancer than for matched control patients with colorectal cancer.
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cancer and matched control patients with colorectal cancer from 
the general population.
Subjects and Methods
Study Population
This multicenter study was collaboration between three research 
groups  from  the  Institute  of  Human  Genetics  (University  of 
Bonn, Bonn, Germany), the Institute of Medical Genetics (School 
of Medicine, Cardiff University, Cardiff, United Kingdom), and 
the Department of Clinical Genetics (Leiden University Medical 
Center,  Leiden,  the  Netherlands).  The  study  population  con-
tained 147 patients with MUTYH-associated polyposis colorectal 
cancer and 272 matched patients with colorectal cancer from the 
general population. Informed consent was obtained according to 
protocols approved by the appropriate national and/or local ethic 
review boards (the Multi-Centre Research Ethics Committee for 
Wales,  ref.  06/MRE09/19;  University  of  Bonn  Ethics  Review 
Board No. 063/04; and Leiden University Medical Center Ethics 
Review  Board  No.  P01.019).  The  Patients  with  MUTYH-
associated polyposis were all biallelic MUTYH mutation carriers 
and included 113 index patients and 34 of their affected siblings. 
Siblings were selected and tested for MUTYH mutations in case 
they had developed colorectal cancer and/or polyps. Genotyping 
was performed as described previously (17–19) [see the Leiden 
Open Variation Database database for all reported MUTYH mu-
tations (20)]. The time of diagnoses ranged from June 15, 1967, 
through August 13, 2001, for Dutch patients; from October 15, 
1977, through March 10, 2006, for German patients; and from 
February 12, 1970, through February 14, 2006 for patients from 
the United Kingdom.
Colon cancer was defined by use of the code C18 and rectal 
cancer was defined by use of the codes C19–C20, according to the 
International Classification of Diseases for Oncology, Edition 3 (21). 
Tumor localization was categorized by the following anatomical 
subsites: proximal colon (consisting of the cecum, appendix, as-
cending colon, hepatic flexure, transverse colon, and splenic flex-
ure; C18.0–C18.5), distal colon (consisting of descending colon 
and  sigmoid;  C18.6–C18.7),  colon  not  otherwise  specified 
(C18.8–C18.9), and rectum (consisting of rectosigmoid and rec-
tum; C19.9–C20.9). Tumor stage was classified according to path-
ological  TNM  stage  (22).  When  the  pathological  stage  was 
unknown, clinical stage was used. For most patients in this study, 
treatment information was not known and could, therefore, not be 
included as a determinant influencing survival. Year of diagnosis 
was  used  as  a  proxy  of  treatment  because  treatment  changed 
during the study period. Survival time was defined as the time from 
the date of diagnosis until death or the end of the study (July 1, 
2006). Patients who were still alive at the end of the study were 
censored on July 1, 2006.
The control patients from the general population were patients 
who were diagnosed with colorectal cancer and whose data were 
derived  from  the  Saarland  Cancer  Registry  in  Germany,  the 
Eindhoven Cancer Registry in the Netherlands, or the Northern and 
Yorkshire Cancer Registry and Information Service in the United 
Kingdom. The Saarland Cancer Registry is the only population-
based cancer registry in Germany, and it has provided internationally 
accepted  high-quality  data  throughout  the  past  35  years  (23). 
Saarland is a state located in southwestern Germany with a popula-
tion of approximately 1.1 million or approximately 1.3% of the 
total  German  population.  The  population  structure  and  the 
health-care system in Saarland are very similar to Germany as a 
whole. The Eindhoven Cancer Registry is the oldest population-
based cancer registry in the Netherlands that collects data from an 
area of 2.4 million inhabitants in southern Netherlands (24). The 
Northern and Yorkshire Cancer Registry and Information Service 
is one of the 11 UK registries and collects data from a population 
of 6.6 million in the center of the United Kingdom.
We aimed to select two control patients with colorectal cancer 
for  each  patient  with  MUTYH-associated  polyposis  colorectal 
cancer who were matched for country, stage at diagnosis, age at 
diagnosis, year of diagnosis, and cancer subsite. The age of diag-
nosis  in  the  matched  German  and  Dutch  control  patients  was 
between 7 years younger and 7 years older than that in the case 
patient. The age of diagnosis in the matched UK control patients 
was between 4 years younger and 4 years older than that in the case 
patient. Cancer subsite was defined as either colon or rectum for 
German and Dutch control patients or as one of the first three 
characters  of  International  Classification  of  Diseases  for  Oncology 
coding—C18, C19, and C20—for UK control patients. Patients 
with  MUTYH-associated  polyposis  colorectal  cancer  from  the 
United Kingdom were matched by the year of diagnosis for the 
period from January 1, 1996, through December 31, 2004. For 
UK patients with MUTYH-associated polyposis colorectal cancer 
CONTEXT AND CAVEATS
Prior knowledge
Individuals with MUTYH-associated polyposis, a recessively inher-
ited  disorder,  have  a  lifetime  risk  for  colorectal  cancer  that  ap-
proaches 100%. It is not known whether specific histological and 
molecular genetic features of such cancers influence tumor behav-
ior and patient survival.
Study design
Characteristics  and  survival  of  European  patients  with  MUTYH-
associated  polyposis  colorectal  cancer  and  matched  population-
based control patients with colorectal cancer were compared.
Contribution
The survival was statistically significantly better for patients with 
MUTYH-associated  polyposis  colorectal  cancer  than  for  control 
patients, even after adjustment for differences in age, stage, sex, 
subsite, country, and year of diagnosis.
Implications
Prospective studies are needed to further investigate this survival 
difference between MUTYH-associated colorectal cancer patients 
and colorectal cancer patients from the general population and to 
investigate whether disease-specific interventions, such as timing 
and type of surgery and chemotherapy, are warranted.
Limitations
Several types of bias are possible, including selection, lead-time, 
and  length-time  biases.  Treatment  was  not  reported  for  many 
patients in this study.
From the Editors
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who were diagnosed before 1996 (n = 19), we used control patients 
who were diagnosed in 1996 because the Northern and Yorkshire 
Cancer Registry and Information Service did not have data before 
1996.  Also,  no  control  data  were  available  for  patients  with 
MUTYH-associated polyposis colorectal cancer who were diag-
nosed after 2004, and so these patients were matched with control 
patients  from  2004.  We  selected  only  control  patients  without 
second tumors because otherwise control patients might be in-
cluded with a possible inheritable form of colorectal cancer that 
might influence the outcome of the survival analysis.
Statistical Analysis
Differences in patient and tumor characteristics between patients 
with MUTYH-associated polyposis colorectal cancer and control 
patients were analyzed by use of the x
2 test. Survival analysis was 
performed  with  Kaplan–Meier  curves  and  Cox  regression.  The 
Cox  model  accounted  for  the  clustering  effect  of  sibling  pairs. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) were pro-
duced  with  robust  standard  errors  by  comparing  patients  with 
MUTYH-associated  polyposis  with  control  patients.  Regression 
analysis was adjusted for the matching variables (ie, age, period of 
diagnosis, site of colon tumor, center, and stage). Moreover, all 
analyses were adjusted for sex. Stratified analyses were performed 
by adjusting for the same set of variables (ie, age as continuous 
variable, period of diagnosis [1967–1979, 1980–1989, 1990–1999, 
or  2000–2006],  site  of  colon  tumor  [colon  or  rectum],  center 
[Germany, United Kingdom, or the Netherlands], stage [I, II, III, 
or IV], and sex [male or female]). We used STATA software, ver-
sion 10.0 (Stata Corp LP, College Station, TX). The proportional 
hazard  assumption  of  MUTYH-associated  polyposis 
was  evaluated  by  applying  Kaplan–Meier  curves.  The  effect  of 
MUTYH-associated polyposis over time satisfied the assumption 
of proportionality because the graphs of the log[2log(survival)] vs 
log(survival time) resulted in graphs with parallel lines. All statis-
tical tests were two-sided.
Results
Crude survival for patients with MUTYH-associated polyposis was 
statistically significantly better than for control patients with colo-
rectal  cancer  from  the  general  population  (log-rank  test  5-year 
survival, P = .002) (Figure 1). Five-year survival was 78% (95% CI 
= 70% to 84%) for patients with MUTYH-associated polyposis 
colorectal cancer compared with 63% (95% CI = 56% to 69%) for 
control patients with colorectal cancer.
Perfect matching of all patients with MUTYH-associated pol-
yposis  and  control  patients  was  not  feasible.  There  were  some 
differences  between  patients  with  MUTYH-associated  polyposis 
and  control  patients,  including  the  number  of  positive  lymph 
nodes (N stage), for which 69 (25%) of the 272 control patients 
had mismatches or missing information; whether metastasis oc-
curred (M stage), in which 81 (30%) had mismatches or missing 
information; tumor subsite for which 33 (12%) had mismatches; 
exact year of diagnosis, for which 76 (28%) had mismatches; and sex, 
for  which  128  (47%)  had  mismatches.  Among  the  272  control 
patients, there was a larger proportion of unknown N or M stage (39% 
or 106 patients) than among the 147 patients with MUTYH-associated 
polyposis (10% or 14 patients). In addition, patients with MUTYH-
associated  polyposis  had  statistically  significantly  more  tumors 
located in the proximal colon (52% or 76 patients) than control 
patients (39% or 107 patients) (P = .015) and diagnosis before 1989 
(19% or 28 patients vs 16% or 44 patients, respectively) (P = .046) 
(Table 1).
After adjustment for age, country, period of diagnosis, stage, 
subsite, and sex, risk of death was statistically significantly lower 
among patients with MUTYH-associated polyposis colorectal cancer 
than  among  control  patients  (HR  =  0.48,  95%  CI  =  0.32  to   
0.72, P < .001) (Table 2).
When the analysis was stratified by stage, the survival benefit 
was higher among patients with stage I and II disease (HR = 0.45, 
95% CI =0.23 to 0.91) than for stage III and IV disease (HR = 0.64, 
95% CI = 0.34 to 1.20) (Table 2). The survival benefit was similar 
among patients with MUTYH-associated polyposis colorectal can-
cer whose tumor was in the colon (HR = 0.42, 95% CI = 0.26 to 
0.67) and among those whose tumor was in the rectum (HR = 0.48 
for  rectum,  95%  CI  =  0.22  to  1.02).  Increased  survival  was 
observed among patients with MUTYH-associated polyposis from 
all three countries (compared with control patients), with that for 
the German group being the highest. When the analysis was strat-
ified  by  the  period  of  diagnosis,  similar  survival  benefits  were 
observed for the period 1967–1989 (HR = 0.49, 95% CI = 0.20 to 
1.17) and 1990–2006 (HR = 0.51, 95% CI = 0.30 to 0.85).
In this study, colorectal cancer was detected during surveillance 
in 25 of the 113 index patients with MUTYH-associated polyposis 
and in nine of the 34 siblings with MUTYH-associated polyposis. 
Colon surveillance was initiated in these 25 index patients and 
nine siblings because of previously identified polyps that caused 
symptoms, including constipation, diarrhea, or blood in the stool 
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Figure 1. Crude survival of patients with MUTYH-associated polyposis 
colorectal  cancer  and  control  patients  with  colorectal  cancer  in  the 
United Kingdom, Germany, and the Netherlands (including a total of 
419 participants, 147 patients with MUTYH-associated polyposis colo-
rectal cancer and 272 control patients). Survival estimates and the cor-
responding  95%  confidence  intervals  (gray  dotted  lines)  for 
MUTYH-associated  polyposis  patients  with  colorectal  cancer  (black 
continuous  line)  and  control  patients  with  colorectal  cancer  (black 
dotted line). After adjustment for differences in age, stage, sex, subsite, 
country, and year of diagnosis, survival remained better for MUTYH-
associated polyposis colorectal cancer patients than for control patients 
(hazard ratio of death = 0.48, 95% CI = 0.32 to 0.72, P < .001).jnci.oxfordjournals.org    JNCI | Articles 1727
(n = 16), or because of a family history of colorectal cancer, most 
often in a parent (n = 18).
In four patients (three index patients and one sibling), the mode 
of detection of colorectal cancer was not known. When we ex-
cluded patients with MUTYH-associated polyposis colorectal can-
cer detected during surveillance from the analysis, we still observed 
statistically significant better survival among MUTYH-associated 
polyposis  patients  than  among  control  patients  with  colorectal 
cancer (Table 2).
Discussion
In a European cohort, survival of MUTYH-associated polyposis 
patients with colorectal cancer was statistically significantly better 
than that of control patients with colorectal cancer. This advantage 
in survival remained statistically significant after adjustments for 
age, stage, colon site, period of diagnosis, country, and sex. In a 
stratification analysis for early-stage (ie, stages I and II) vs late 
stage (ie, stages III and IV) cancers, the survival benefit for patients 
with  MUTYH-associated  polyposis  colorectal  cancer  compared 
with control patients with colorectal cancer was slightly higher 
among patients with early-stage colorectal cancer (HR = 0.45, 95% 
CI = 0.23 to 0.91) than among those with later stage colorectal 
cancer (HR = 0.64, 95% CI = 0.34 to 1.20).
To our knowledge, this is the first study to examine survival of 
MUTYH-associated polyposis patients with colorectal cancer com-
pared with that of matched control patients with colorectal cancer 
from  the  general  population.  Patients  with  MUTYH-associated 
polyposis  colorectal  cancer  were  recruited  from  the  largest 
MUTYH-associated polyposis cohort so far assembled.
Table 1. Characteristics of the total study population (n = 419), including 147 patients with MUTYH-associated polyposis colorectal 
cancer (MAP CRC) and 272 control patients with CRC
Characteristic Patients with MAP CRC Control CRC patients Total population
Male, No. (%) 82 (56) 124* (46)† 206 (49)
Index patient, No. (%) 113 (77) 272 385
Siblings, No. (%) 34 (23) 0 34
Method of detection CRC    
  Symptomatic, No. (%) 109 (74) 272 381
  Surveillance, No. (%) 34 (23) 0 34
  Unknown, No. (%) 4 (3) 0 4
Median age (range), y 54.0 (32.1–81.1) 52.1 (28.5–79.1) 53.1 (28.5–81.1)
Location, No. (%)    
  Proximal colon 76 (52) 107 (39)‡ 183 (44)
  Distal colon 21 (14) 73 (27) 94 (22)
  Rectum 38 (26) 65 (24) 103 (25)
  Colon, not otherwise specified 12 (8) 18 (7) 30 (7)
  Unknown 0 (0) 9 (3) 9 (2)
T stage, No. (%)    
  0 or in situ 6 (4) 6 (2) 12 (3)
  1 15 (10) 33 (12) 48 (12)
  2 22 (15) 38 (14) 60 (14)
  3 50 (34) 118 (43) 168 (40)
  4 8 (5) 18 (7) 26 (6)
  Unknown 46 (31) 59(22) 105 (25)
N stage, No. (%)    
  0 85 (58) 136 (50) 221 (53)
  1 33 (23) 54 (20) 87 (21)
  2 15 (10) 29 (10) 44 (11)
  Unknown 14 (10) 53 (20) 67(16)
M stage, No. (%)    
  0 125 (85) 161 (59)§ 286 (68)
  1 12 (8) 25 (9) 37 (9)
  Unknown 10 (7) 86 (32) 96 (23)
Period of diagnosis, No. (%)    
  1967–1979 12 (8) 20 (7) 32 (8)
  1980–1989 16 (11) 24 (9) 40 (10)
  1990–1999 69 (47) 136 (50) 205 (49)
  2000–2006 50 (34) 92 (34) 142 (34)
Country, No. (%)    
  Germany 55 (37) 106 (39) 161 (38)
  United Kingdom 42 (29) 66 (24) 108 (26)
  the Netherlands 50 (34) 100 (37) 150 (36)
*  Unknown for six patients.
†  P = .046. x2 test was used. All statistical tests were two-sided.
‡  P = .015.
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Given the retrospective character of the study, there are many 
possible biases and limitations that might lead to an overestimation 
or an underestimation of survival benefits (eg, selection, lead-time, 
and  length-time  biases).  Treatment  was  not  reported  for  many 
patients in this study.
Selection Bias
It can be expected that patients from families with several affected 
members who survived their cancer may be more likely to come to 
the  attention  of  clinical  geneticists  than  those  from  families  in 
which  all  affected  members  died  from  their  disease.  Therefore, 
cohorts of patients who are recruited through genotyping studies 
could  be  biased  toward  those  with  better  prognosis.  This  form   
of  bias  may  have  been  operating  in  previous  studies  of  Lynch   
syndrome–specific survival (9,25). However, a number of observa-
tions are counter to this argument. First, Hampel et al. (26) reported 
that index patients from Lynch syndrome families are younger at 
diagnosis of colorectal cancer than other mutation-positive patients 
in their family. Therefore, patients who come to medical attention 
through genetic testing do not necessarily have a milder phenotype. 
Second,  although  patients  who  die  young  or  shortly  after  their 
diagnosis of colorectal cancer might not come to the immediate 
attention of clinical geneticists, the nonaffected members of their 
family may be referred for genetic counseling. MUTYH genotyping 
can be done on DNA isolated from archived formaldehyde-fixed 
tumor tissue (27) of a deceased patient or in the DNA isolated from 
blood of parents and/or siblings who are still alive. Third, patients 
with MUTYH-associated polyposis who have a relatively mild phe-
notype (eg, nonaggressive colorectal cancer at a later age) are likely 
be  underrepresented  in  our  cohort  of  patients  with  MUTYH-
associated polyposis because the likelihood that they could have 
inherited a predisposition toward colorectal cancer may be lower.
Another selection bias might be that patients with MUTYH-
associated polyposis who have no polyps or only a few polyps (eg, 
0–10 polyps) are likely to be underrepresented in our cohort, par-
ticularly when there is no family history of colorectal cancer in a 
sibling.  MUTYH  mutation  screening  in  population-based  colo-
rectal cancer patients has shown that one-third of biallelic muta-
tion carriers with colorectal cancer have no or only few polyps (eg, 
0–10 polyps) (15,28). Such patients are less frequently referred for 
molecular genetic analysis than patients with more florid forms of 
polyposis (eg, more than 10 polyps, numerous or multiple polyps). 
It is not known whether prognosis of patients with no or only   
few  polyps  (eg,  0–10  polyps)  differs  from  that  of  patients   
with  MUTYH-associated  polyposis  with  colorectal  cancer  and 
polyposis.
Finally,  for  UK  patients  with  MUTYH-associated  polyposis 
colorectal cancer who were diagnosed before 1996 (n = 19), we 
used  control  patients  who  were  diagnosed  in  1996  because  the 
Cancer Registry did not have data before 1996. This procedure 
could have lead to better survival in control patients because treat-
ment of cancer is expected to have improved between 1970 and 
1996, the period in which the 19 UK case patients were diagnosed 
with colorectal cancer. However, after adjustment for date period 
in  the  multivariable  Cox  regression  analysis,  results  remained 
unchanged.
Lead-Time and Length-Time Bias
Heightened awareness among and surveillance of high-risk patients 
lead to diagnoses at an earlier stage of disease (lead-time bias) and 
might account for an apparent survival advantage. Length-time 
bias is also a consideration if screening tests lead to detection of 
asymptomatic indolent tumors. Patients with MUTYH-associated 
polyposis who are enrolled in surveillance programs could gain a 
survival benefit by early detection.
As  expected,  there  are  differences  in  stage  between  patients 
whose disease was detected by surveillance and those whose disease 
was detected symptomatically; stage I disease was diagnosed in 14 
(41%) of the 34 patients during surveillance and in 21 (19%) of the 
109 patients diagnosed symptomatically. It should be noted that, 
after  adjustment  for  other  factors  including  stage,  exclusion   
of patients with MUTYH-associated polyposis diagnosed during 
surveillance,  survival  benefit  (ie,  hazard  ratio)  did  not  change 
(Table 2, second column).
Other Possible Biases
Another  explanation  of  the  better  survival  of  patients  with 
MUTYH-associated  polyposis  compared  with  that  of  control 
patients might be that patients with MUTYH-associated polyposis 
receive  more  extensive  surgery  because  they  usually  have  more 
polyps. However, the overall survival of patients with MUTYH-
associated  polyposis  might  actually  be  worse  because  they  are 
Table 2. Cox regression analysis for patients with MUTYH-
associated polyposis (MAP) colorectal cancer (CRC) compared 
with control CRC patients*
Analysis
Hazard ratio  
(95% confidence 
interval)
Hazard ratio  
(95% confidence 
interval)
All patients  
(n = 419)
Symptomatic 
patients  
(n = 381)†
Overall (MAP vs  
    control CRC)
0.48 (0.32 to 0.72) 0.48 (0.32 to 0.73)
Stratified  
  Stage  
     I or II 0.45 (0.23 to 0.91) 0.47 (0.21 to 1.04)
    III or IV 0.64 (0.34 to 1.20) 0.64 (0.33 to 1.22)
  Site of diagnosis  
    Colon 0.42 (0.26 to 0.67) 0.40 (0.24 to 0.66)
    Rectum 0.48 (0.22 to 0.1.02) 0.55 (0.24 to 1.25)
  Country  
    United Kingdom 0.66 (0.22 to 1.97) 0.76 (0.25 to 2.32)
    Germany 0.28 (0.10 to 0.74) 0.28 (0.10 to 0.82)
    the Netherlands 0.49 (0.31 to 0.79) 0.45 (0.27 to 0.74)
  Calendar period  
    1967–1989 0.49 (0.20 to 1.17) 0.40 (0.15 to 1.03)
    1990–2006 0.51 (0.30 to 0.85) 0.52 (0.31 to 0.88)
*  Data are from the Cox model with robust standard errors. The model was 
adjusted for the matching variables, age, country, period of diagnosis, stage, 
and site of colorectal cancer, and also for sex.
†  Symptomatic patients are MUTYH-associated patients who underwent colon 
screening because of symptoms (eg, anemia, nausea, diarrhea, or blood 
in the stool) and had colorectal cancer at presentation. MUTYH-associated 
patients in whom colorectal cancer was detected during surveillance because 
of a positive family history or previously identified polyps were excluded from 
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prone to develop multiple cancers. Indeed, 46 (31%) of the 147 
patients with MUTYH-associated polyposis in this study actually 
had two or more colorectal cancers at the time of diagnosis or 
developed a second colorectal cancer later on in life.
Immune Response Differences and Survival Advantage
An  active  immune  response  (represented  by  a  high  number  of 
tumor-infiltrating  lymphocytes)  is  strongly  associated  with  better 
survival rates in control patients with colorectal cancer (29–31). It 
has been proposed that the immune system of patients with high 
microsatellite  instability  and  mismatch  repair–deficient  tumors 
might be more active than that of colorectal cancer patients in the 
general  population,  which  would  lead  to  better  survival  (32,33). 
Because of a defect in the DNA repair, more mutant proteins are 
expected in the mismatch repair–deficient tumors than in sporadic 
colon tumors. As a result, more peptide fragments of mutant proteins 
might  be  presented  at  the  cell  surface  of  the  mismatch  repair– 
deficient cancer cells, which activate the immune system. Furthermore, 
the enhanced mutation rate in these tumors may also induce a muta-
tion burden that is not compatible with tumor cell survival.
We have previously shown (34) that MUTYH-associated pol-
yposis  colorectal  cancers  share  similar  characteristics  with  mis-
match repair–deficient cancers, including a preferential proximal 
location, a high rate of mucinous morphology, and an increased 
level  of  tumor-infiltrating  lymphocytes.  The  disruption  of 
MUTYH protein function in MUTYH-associated polyposis carci-
noma cells might lead to more oxidative DNA damage and gener-
ation  of  mutant  peptides  that  could  be  presented  to  cytotoxic   
T cells through the expression of HLA class I receptors. It has, 
indeed, been shown that loss of expression of HLA class I recep-
tors has been frequently identified in MUTYH-associated polypo-
sis colorectal cancers and in mismatch repair–deficient colorectal 
tumors (35,36,37), indicating that these tumors may be subject to 
strong selective pressure that favors outgrowth of cancer cells that 
acquire an immune-evasive phenotype (37).
In conclusion, in this study, patients with MUTYH-associated 
polyposis  colorectal  cancer  had  statistically  significantly  better 
survival than matched control patients. The reasons for this differ-
ence remain unknown, but a compromised base excision repair 
system could render MUTYH-associated polyposis colorectal can-
cers more immunogenic than sporadic colorectal cancers, which 
are characterized predominantly by chromosomal instability. This 
survival  difference  may  have  implications  for  clinical  decision 
making  in  relation  to  the  timing  and  type  of  interventions 
required, such as surgery and chemotherapy. Future prospective 
studies  are  needed  to  confirm  this  survival  difference  between 
MUTYH-associated colorectal cancer patients and colorectal cancer 
patients from the general population.
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